Aviva PLC Allogene Therapeutics, Inc. Transaction History

Aviva PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$25.79 - $39.02 $902,727 - $1.37 Million	-35,003 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$25.24 - $43.45 $716,311 - $1.23 Million	-28,380 Reduced 44.78%	35,003 $883,000
Q3 2020 Nov 12, 2020	BUY	$32.38 - $44.96 $285,688 - $396,682	8,823 Added 16.17%	63,383 $2.39 Million
Q2 2020 Aug 13, 2020	SELL	$18.39 - $54.04 $2.35 Million - $6.89 Million	-127,530 Reduced 70.04%	54,560 $2.34 Million
Q1 2020 May 14, 2020	BUY	$18.22 - $28.25 $2.06 Million - $3.2 Million	113,180 Added 164.24%	182,090 $3.54 Million
Q4 2019 Feb 10, 2020	BUY	$24.82 - $31.4 $1.71 Million - $2.16 Million	68,910 New	68,910 $1.79 Million

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $262M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.